Clinical Research
BioCity Biopharma (BioCity) announced its endothelin receptor type A (ETA) selective antagonist SC0062 met the primary endpoint of proteinuria reducti...
July 09, 2024 | News
Zhejiang Doer Biologics, a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announc...
July 08, 2024 | News
Hinova Pharmaceuticals a leading biopharmaceutical company dedicated to developing innovative cancer therapies, today announced that the U.S. Food an...
July 08, 2024 | News
- Following its initial approval for the treatment of relapsed/refractory multiple myeloma (R/R MM), XPOVIO® has now received approval as a monoth...
July 08, 2024 | News
Ascentage Pharma a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies ...
July 04, 2024 | News
MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Co., Ltd. announced the completion of the regulatory review by the Pharmaceuticals an...
July 03, 2024 | News
N-Power Medicine, a company reinventing the clinical trial process, is collaborating with Merck, known as MSD outside the United States and Canada, to enab...
July 02, 2024 | News
Provides Lilly access to Radionetics’ proprietary GPCR targeting small molecule radiopharmaceuticals Radionetics to receive $140 million upfront p...
July 02, 2024 | News
Harvest Integrated Research Organization (HiRO), a full-service, boutique global CRO, is excited to announce its latest strategic move with the successful ...
July 02, 2024 | News
Sirnaomics , a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced that the Group h...
July 01, 2024 | News
The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, today announced the expansion of its central labo...
June 28, 2024 | News
HUADONG MEDICINE, through its wholly-owned subsidiary Hangzhou Zhongmei HuaDong Pharmaceutical CO. LTD (Zhongmei HuaDong), has recently announced positive ...
June 27, 2024 | News
- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treat...
June 27, 2024 | News
Developed a 'Niclosamide-based multi-treatment drug' that can simultaneously treat mosquito-borne viral infections such as four serotypes of dengue virus...
June 26, 2024 | News
Most Read
Bio Jobs
News
Editor Picks